Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Charles Rosenbaum"'
Autor:
Charles Rosenbaum
Publikováno v:
Oncology Times. 28:5-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32f7af34d352c773f2b2e1bee770580a
https://doi.org/10.1097/01.cot.0000294386.19152.d4
https://doi.org/10.1097/01.cot.0000294386.19152.d4
Publikováno v:
Cancer. 46:1781-1784
Estrogen receptor assays were performed on tumor specimens from 6 male patients with documented breast cancer. Five out of six (83%) males had positive ER assays with values ranging from 23-384 femtomoles per mg cytosol protein. A review of the liter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49af2bcffb7192b52c1a97c179f45be7
https://doi.org/10.1002/1097-0142(19801015)46:8<1781::aid-cncr2820460814>3.0.co
https://doi.org/10.1002/1097-0142(19801015)46:8<1781::aid-cncr2820460814>3.0.co
Autor:
John Horton, David A. Schoenfeld, Ronald C. Deconti, Charles Rosenbaum, J Wolter, Geoffrey Falkson
Publikováno v:
Cancer. 50:2757-2762
This randomized study, conducted by the Eastern cooperative Oncology Group, compared Adriamycin (doxorubicin) (70 mg/m2) versus vincristine (1.4 mg/m2) and Adriamycin (50 mg/m2); and cyclophosphamide (750 mg/m2) versus vincristine (1.4 mg/m2), actino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dcd2fb365bea9e50d55cf0a66cddf47
https://doi.org/10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co
https://doi.org/10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co
Autor:
Kenneth B. Olson, John Horton, Charles Rosenbaum, Samuel G. Taylor, Donald H. Baxter, Thomas J. Cunningham, L. R. Nelson, Robert W. Sponzo
Publikováno v:
Cancer. 36:1269-1276
The effectiveness of DTIC in the treatment of Grade III and IV astrocytomas was analyzed in two phases. In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8cf4858af4d5d7ef1b729c65e6f626f
https://doi.org/10.1002/1097-0142(197510)36:4<1269::aid-cncr2820360412>3.0.co
https://doi.org/10.1002/1097-0142(197510)36:4<1269::aid-cncr2820360412>3.0.co
Autor:
Colin B. Begg, Charles G. Moertel, John M. Bennett, Douglass C. Tormey, William D. Dewys, Murray N. Silverstein, Philip T. Lavin, John Horton, Roland T. Skeel, Martin M. Oken, Charles Rosenbaum, Pierre R. Band, Martin H. Cohen, Harold O. Douglass, Robert W. Sponzo, Charles P. Perlia, Joseph R. Bertino, Gerhard J. Johnson, Paul F. Engstrom, Ediz Z. Ezdinli
Publikováno v:
The American Journal of Medicine. 69:491-497
The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31 percent for favorable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42ab9c6277b52dca4a627565f96810bb
https://doi.org/10.1016/s0149-2918(05)80001-3
https://doi.org/10.1016/s0149-2918(05)80001-3
Autor:
Martin Schlesinger, Stanley Cowen, Richard D. Marks, Richard Protzel, Harvey Kalan, Herbert Sillman, David Sievers, Michael Drickman, Lester Winkler, Avrum Z. Bluming, Jack Garfinkle, Norman Koenig, Steven Newman, Jerome Belzer, Charles Rosenbaum, Alan Bricklin, Marvin Calmenson, Stanley Rossman, Nathan Gittleman, Leonard Kovner, Donald Bernstein, Bernard S. Lewinsky, Douglas Morrow, Harvey S. Frey, Stephen H. Greenberg, Robert Baum, Ronald W. Thompson, Jason D. Green, Gary M. Dosik, Alan Pomerantz, Clifton Portnoff, Nathan W. Green, Hugh Raphael, Barry Lowitz, Mary Lou Ozohan, Aaron G. Fingerhut, Bruce Zeitz, Robert Harwood, Ronald Citronbaum
Publikováno v:
Annals of Surgery. 204:136-147
Between 1977 and 1983, 150 women with primary breast cancer, ranging in age from 26 to 84, were treated with a breast-sparing procedure involving lumpectomy, axillary node dissection, external beam radiotherapy, and 192-iridium implant. Median follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85660e4c6a2d78be5e30941010ad68bb
https://doi.org/10.1097/00000658-198608000-00007
https://doi.org/10.1097/00000658-198608000-00007
Publikováno v:
Cancer. 46:2919-2921
88 patients with advanced breast cancer were retrospectively reviewed to compare (ER) estrogen receptor data with response to cytotoxic chemotherapy. All assays were done in a single laboratory and all patients were cared for at a single institution.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81db6b31fbc0d13dfe676f181cae2987
https://doi.org/10.1002/1097-0142(19801215)46:12+<2919::aid-cncr2820461434>3.0.co
https://doi.org/10.1002/1097-0142(19801215)46:12+<2919::aid-cncr2820461434>3.0.co
Publikováno v:
Medical and pediatric oncology. 3(2)
An examination of certain moral tensions that have developed in clinical cancer experimentation is offered. It is argued that the individual partner must be addressed in his singular unique position, rather than as a potential for the future good.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e4d73dc49cde3a25531ee23b18a768
https://pubmed.ncbi.nlm.nih.gov/327251
https://pubmed.ncbi.nlm.nih.gov/327251
Autor:
Anthony R. Paul, Arlene S. Ash, Ernest C. Borden, Geoffrey Falkson, J. Frederick Laucius, Horatio T. Enterline, Harvey J. Lerner, Charles Rosenbaum
Publikováno v:
American journal of clinical oncology. 5(4)
Patients WITH OBJECTIVELY MEASURABLE soft tissue sarcomas, osteosarcomas, chondrosarcomas, and mesotheliomas were treated with dibromodulcitol (DBD) (180 mg/m2 p.o. days 1–10 q4 wks.), ICRF-159 (300 mg/m2 p.o. tid days 1–3 q4 wks.), or maytansine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a99373412f647e5641ce68c6696a6c8
https://pubmed.ncbi.nlm.nih.gov/6956236
https://pubmed.ncbi.nlm.nih.gov/6956236
Publikováno v:
The Prostate. 12(2)
A group of 19 patients with advanced (Stage D) prostate cancer were treated with one of three dose levels of the anti-estrogen tamoxifen, 10 mg (3 patients), 20 mg (8 patients), or 30 mg (8 patients) daily. Five patients had received no prior systemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9bc33d48aa5cef225dc4b873596b929
https://pubmed.ncbi.nlm.nih.gov/3368405
https://pubmed.ncbi.nlm.nih.gov/3368405